Form 4: TriSalus Life Sciences Director Acquires Shares in Open Market Transaction

Director Mats Wahlstrom purchased 5,000 shares of TriSalus Life Sciences stock at an average price of $4.55.

Summary

• Mats Wahlstrom, a director of TriSalus Life Sciences, acquired 5,000 shares of common stock on November 22, 2024.
• The shares were purchased at a weighted average price of $4.55, with individual transaction prices ranging from $4.45 to $4.63.
• Following the transaction, Mr. Wahlstrom directly owns 15,727 shares.
• He also indirectly owns 1,254,259 shares through Leonard Capital LLC and 1,370,028 shares through HW Investment Partners, LLC.
• Mr. Wahlstrom shares voting and investment discretion with his spouse regarding the shares held by Leonard Capital LLC.
• He is also a managing member of HW Investment Partners, LLC and shares voting and investment discretion with respect to the shares held by that entity.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase indicates confidence, but it's a routine transaction.

Positives

• The director's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
• The purchase increases the director's stake in the company, aligning his interests with those of other shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the United States.
• The level of detail provided in this filing is consistent with SEC requirements.
• The transaction is relatively small compared to the overall market capitalization of the company, but it is still relevant as it reflects the director's personal investment decisions.

Stakeholder Impact

• The purchase may have a minor positive impact on shareholder sentiment.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

TriSalus Life Sciences, insider trading, stock purchase, Mats Wahlstrom, director, share acquisition, TLSI